Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daniel Chancellor

Principal Analyst

London, UK

Latest From Daniel Chancellor

The Next Mega-Blockbusters Are Already Approved

The success of a drug depends on investment and lifecycle management. Keytruda is the most valuable drug in the industry, while trendy GLP-1 agonists are a prominent drug class. 

Commercial Sales & Earnings

The Growing Pains Of Chinese Biotech

The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.

Asia Pacific China

The State Of TechBio Going Into 2024

The long-term success of TechBio is dependent upon the flow of investment and alliances with mature life sciences companies. This collaborative model has proven many times over to be an ideal framework to develop new treatments for patients.

Artificial Intelligence Business Strategies

The Misalignment Of Pharma Pipelines

Portfolio decisions for pharma pipelines are multifactorial, although patient need perhaps does not get the attention it merits. Rather, the gravitational pull around risk, investment return, and regulatory incentive tilts the pharma pipeline toward overconcentration in hot therapy areas.

Research & Development Strategy

Pharma Innovation: Europe Is Being Edged Into Third Place

With a declining share of global R&D and investment, Europe risks the pharmaceutical industry being increasingly molded in the image of others.

Europe Research & Development

European Investor Sentiment Rebounds On Cell And Gene Therapy

Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising, platform development to manufacturing.

Gene Therapy Europe
See All
UsernamePublicRestriction

Register